Zeposia

September 22, 2020September 22, 2020

Gilenya Remains Favorite S1P Receptor Modulator in US, But Zeposia May Catch Up, Survey Finds

News, Zeposia

Among oral sphingosine-1-phosphate (S1P) receptor modulators for multiple sclerosis (MS), Novartis’s Gilenya (fingolimod) remains physicians’ favorite in the U.S., but prescriptions of recently-launched Bristol Myers Squibb’s Zeposia (ozanimod) are beginning ... Read more

September 3, 2020September 4, 2020

#MSVirtual2020 – Zeposia Still Prevents Relapses in Relapsing MS Patients After 3 Years, Trial Data Show

News, Zeposia

Zeposia (ozanimod) oral capsules continue to safely and effectively prevent relapses and disability progression in people with relapsing forms of multiple sclerosis (MS), according to three-year data from a ... Read more

June 3, 2020June 4, 2020

Zeposia, Daily Oral Treatment for Relapsing MS, Now Available in US

News, Zeposia

Zeposia (ozanimod), a newly approved oral capsule treatment for relapsing forms of multiple sclerosis (MS), is now commercially available in the United States, its manufacturer, Bristol Myers Squibb, announced. “We are ... Read more

May 27, 2020June 2, 2020

Zeposia Receives European Commission Approval for Adults with Active RRMS

News, Zeposia

The European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) who have active disease based on clinical or imaging features. The ... Read more

April 9, 2020April 28, 2020

Zeposia Is Now Approved, But Expect Delays

Columns, Covid-19, Silver Linings - a Column by Jennifer Powell, Zeposia

Zeposia’s recent approval in the U.S. is exciting news for all in the MS community. Unfortunately, we will need to table that excitement a bit longer. Despite its approval, ... Read more

March 30, 2020April 7, 2020

CHMP Favors Zeposia (Ozanimod) as Oral Treatment for Active RRMS in EU

News, Zeposia

The Committee for Medicinal Products for Human Use (CHMP) has recommended Zeposia (ozanimod) oral capsules to be approved in the European Union (EU) to treat adults with active relapsing-remitting multiple sclerosis ... Read more

March 26, 2020May 27, 2020

FDA Approves Zeposia (Ozanimod), Oral Therapy for All with Relapsing MS

Covid-19, News, SPMS, Zeposia

The U.S. Food and Drug Administration (FDA) has approved Zeposia (ozanimod) oral capsules to treat adults with relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS (RRMS), active secondary progressive MS (SPMS), and ... Read more